Search

everythinglearnresearchcommunity

for

Search:↓

Anageninc stopping the sale of Pyrilutamide due to a cease and desist order from Kintor, with some speculating that it was either a hoax or subpar product.

A 17-year-old shared progress pictures after using RU58841 and Minoxidil for 2 months, showing significant hair regrowth. Another user commented on the impressive results achieved in a short time.

The user is using RU58841, dutasteride, and minoxidil for hair loss, storing RU58841 in the fridge and applying it nightly. They report more baby hairs on the temples but are unsure if it's due to new growth or miniaturization, and seek advice on mixing and results from RU58841.

The conversation discusses maintaining hair regrowth using minoxidil and finasteride and whether using gt20029, which degrades androgen receptors, would affect this. Fluridil, a similar treatment, can disable over 90% of active androgen receptors.

The user is considering stopping RU58841 due to inconvenience and potential side effects, while continuing with oral minoxidil and dutasteride. Another user shared their experience of stopping RU58841 without significant hair shedding while on dutasteride and minoxidil.

The conversation discusses using estradiol and its derivatives for hair loss without causing feminization. Users mention alternatives like alfatradiol, topical 17b-Estradiol, and DIM (Diindolylmethane).

Kintor's phase III trial for pyri (KX-826) showed promising safety and efficacy results, with no drug-related sexual dysfunction reported. Users discussed their experiences with pyri, Minoxidil, Dutasteride, and concerns about the validity of the study results.

The conversation is about finding a reliable source to purchase Pyrilutamide that ships to the UK. There's also an openness to using RU58841 as an alternative.

A 26-year-old individual treating hair loss since 19, using a regimen of Finasteride, Cyproterone, Oral Minoxidil, Microneedling, Dutasteride, and newly added RU58841. They're seeking advice from other RU58841 users about their experiences.

Magnesium L-Threonate may help treat balding by reducing DKK-1 expression without affecting DHT. Users discuss its potential effectiveness and application methods, with some considering trying it topically.

Kintor's GT20029, a treatment for hair loss, has completed Phase 1 successfully, showing promise as an androgen receptor degrader that could potentially regrow hair. It is considered more effective than Pyrilutamide, with infrequent dosing and minimal systemic absorption.

A 23-year-old started using 0.5mg Dutasteride and 2.5mg Minoxidil daily for hair loss and is considering adding RU58841 or GHK-cu. Users suggest waiting a few months before adding anything and mention Koshine's kx-826 as a potentially better alternative to RU58841.

The conversation is about a user experiencing hair shedding after using a brand of RU58841, questioning its effectiveness and safety. Concerns are raised about RU58841 being an abandoned research chemical and the use of heavy oils like castor and argan oil potentially affecting absorption.

Tretinoin can make minoxidil more effective for hair loss treatment, but some users did not see improved hair density with this combination and had better results with dutasteride.

The effects of Finasteride on hair loss and its side-effects, such as aching balls. The user has been taking it for two years with no changes to the symptom.

The user has been using finasteride for a year to stop hair loss and is considering adding RU58841 instead of minoxidil to further inhibit DHT. Another user suggests adding dutasteride for better DHT inhibition, but the original user cannot access it and is considering RU58841 despite potential side effects.

Promising hair loss treatments in clinical trials include Pyrilutamide, GT20029, CB-03-01, and PP405, with potential market releases between 2027 and 2029. Hair cloning remains experimental and expensive, while existing treatments like finasteride, minoxidil, and microneedling continue to be used.

Alfatradiol is used as a mild treatment to slow or stabilize hair loss, often alongside finasteride and pumpkin seed oil. Users report reduced shedding and minimal side effects, but minoxidil is noted as more effective for regrowth.

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. The user inquires if RENU Biogen is a DHT inhibitor.

MinoxidilMax is now selling a product called Ruderma, which contains RU58841, a chemical used for hair loss treatment. Some users question the legitimacy of the company, while others discuss the standard concentration of RU58841 and mention that both men and women use finasteride for hair loss.

A 22-year-old trans woman has been on 6mg estradiol enanthate for five months. She reports thicker and healthier hair but not much regrowth yet.

The user experienced severe side effects from finasteride, including cognitive and sexual issues, despite its effectiveness for hair growth. They are considering switching to RU58841 and seek insights from others who have made a similar change.

Minoxidil's effectiveness is limited by the need for sulfation and proper transport to hair follicles, with tretinoin potentially enhancing its effects by promoting enzyme activity and keratinocyte differentiation. Tretinoin may improve minoxidil's response by boosting the expression of necessary enzymes and transporters.

A user shared their hair regrowth progress using Dutasteride, topical Minoxidil, Spironolactone, and Estradiol Valerate injections as part of hormone replacement therapy for transitioning. They experienced significant hair improvement and personal satisfaction but caution against this approach for non-transitioning individuals due to irreversible changes.

Hair loss treatments are generally categorized as anti-androgens, like finasteride and RU58841, which prevent hair loss by targeting DHT, and growth stimulators, such as minoxidil, rosemary oil, microneedling, and LLLT, which promote hair growth by increasing blood flow and growth factors. The user is seeking to confirm these categories and understand if there are other treatments or mechanisms of action.

The user was rejected from participating in a clinical trial for an extended-release oral Minoxidil due to having rheumatoid arthritis, despite initially being accepted. They had stopped using Dutasteride and Minoxidil to qualify but continued using other treatments like RU58841 and red light therapy.

RU58841 remains active for several hours after application, and it's suggested to wait a few hours before washing it off to maintain its effectiveness. There is a concern about potential transfer to others if they touch the hair shortly after application.

Finasteride and dutasteride are discussed for hair loss, with concerns about their effects on neurosteroids and potential side effects like depression. Alternatives like topical estrogen and lifestyle changes are considered, with varying opinions on mental health and hair regrowth.

The FDA will now require only one clinical trial for drug approval, potentially speeding up the release of hair loss treatments like PP405. Pelage is expected to present full results of PP405 Phase 2a trials and move to Phase III in mid-2026.

The conversation discusses the potential of topical rapamycin, metformin, and alpha-ketoglutarate (a-KG) for hair growth, with skepticism expressed about their effectiveness based on personal experience and existing use. It also mentions AICAR, known as cardarine or GW, which is not suitable for long-term use due to cancer risks in animal studies and its similarity to metformin.